-
Kodiak Sciences Inc. (KOD) Misses Q3 EPS by 14c
-
H.C. Wainwright Upgrades Kodiak Sciences Inc. (KOD) to Buy
-
Kodiak reports positive 20-week data for macular edema treatment KSI-101
-
JPMorgan Upgrades Kodiak Sciences Inc. (KOD) to Overweight
-
Barclays Upgrades Kodiak Sciences Inc. (KOD) to Equalweight
-
Jefferies Starts Kodiak Sciences Inc. (KOD) at Buy, 'MESI mkt oppty could be substantial, likely 2x UME'
-
H.C. Wainwright Reiterates Neutral Rating on Kodiak Sciences Inc. (KOD)
-
Kodiak Sciences Inc. (KOD) PT Raised to $5 at H.C. Wainwright
-
JPMorgan Upgrades Kodiak Sciences Inc. (KOD) to Neutral
-
Kodiak Sciences Inc. (KOD) Tops Q2 EPS by 1c
-
Kodiak Sciences Inc. (KOD) Tops Q1 EPS by 214c
-
Kodiak Sciences Inc. (KOD) Tops Q1 EPS by 214c
-
H.C. Wainwright Reiterates Neutral Rating on Kodiak Sciences Inc. (KOD)
-
Kodiak Sciences Inc. (KOD) Tops Q4 EPS by 7c
-
Jefferies Upgrades Kodiak Sciences Inc. (KOD) to Buy
-
Kodiak Sciences Inc. (KOD) Tops Q3 EPS by 6c
-
Goldman Sachs Reiterates Sell Rating on Kodiak Sciences Inc. (KOD)
-
H.C. Wainwright Starts Kodiak Sciences Inc. (KOD) at Neutral
-
Kodiak Sciences Inc. (KOD) Tops Q2 EPS by 1c

